Moving the needle on vaccine preventable diseases.

MMGH uses a unique combination of rigorous academic research, tailor-made teams, specialist knowledge, industry-specific experience, state-of-the-art tools and independent thinking, to provide trusted advice and implementable solutions for programmes and products related to Vaccine Preventable Diseases, and Neglected Tropical Diseases, within the public health sphere.

Filters

  • Focus Areas
    Projects - Focus Areas
    • Access
    • Evaluation
    • Implementation
    • Policy & Strategy
  • Vaccine Preventable Diseases
    Projects - Vaccine Preventable Diseases
    • Cholera
    • COVID-19
    • Diphtheria
    • Enteric Fever
    • Human Papillomavirus
    • Influenza
    • Japanese Encephalitis
    • Leishmaniasis
    • Measles-Rubella
    • Meningitis
Search
Sort By (Projects)
Image Credit: Vaxxas
2021 — Ongoing

Definition and market sizing of the use cases for micro-array...

MMGH is supporting the Vaccine Innovation Prioritisation Strategy on defining potential use cases for Typhoid Conjugate Vaccine microarray patches (TCV-MAPs) this work will include a demand forecast of the potential…
Client
Gavi, The Vaccine Alliance
2021 — Ongoing

MR-MAPs initial Full Vaccine Value Assessment...

In partnership with the London School of Hygiene and Tropical Medicine and Global Health Visions, support the development of an initial Full Vaccine Value Assessment of Measles-Rubella micro-array patches (MR-MAPs),…
Client
UNICEF
Image Credit: CDC
2019 — 2019

Leishmaniasis vaccine product development plan...

MMGH created a product development plan to guide the University of York in the further development of a candidate leishmaniasis vaccine. The plan incorporates the definition of a target product…
Client
University of York
Image Credit: MMGH/Carsten Mantel
2019 — Ongoing

Advocacy for the Vaccine Against Invasive non-typhoidal Salmonella (Vacc-iNTS) project...

MMGH is part of the Vaccine Against Invasive non-typhoidal Salmonella (Vacc-iNTS) consortium, made up of 12 partners from eight different countries including three disease-endemic countries. The initiative advances the development…
Client
EU Commission
2019 — Ongoing

Definition and market sizing of the use cases for micro-array...

MMGH supports the WHO's Vaccine Product & Delivery Research department in defining and sizing (including a demand forecast) the use cases for a Measles Rubella vaccine micro-array patch (MAP). The…
Client
World Health Organisation (WHO)
Image Credit: CDC
2019 — 2020

Demand forecast and financial sustainability analysis for a group B...

MMGH supported the WHO Initiative for Vaccine Research (IVR) in developing a variety of forecast scenarios for the demand of a group B streptococcal (GBS) vaccine administered through maternal immunisation.…
Client
World Health Organisation (WHO)
2019 — 2020

Operationalisation of group B streptococcal maternal vaccination...

MMGH supported the WHO Initiative for Vaccine Research (IVR) in preparing a report on the considerations for operationalising group B streptococcal (GBS) maternal vaccination as part of a Public Health…
Client
World Health Organisation (WHO)
Image Credit: Mika Baumeister
2019 — 2020

Development of European Region Immunisation Agenda 2030...

MMGH supported the Bill & Melinda Gates Foundation in assessing the public health and financial viability of a macrofilaricide drug to accelerate the elimination of onchocerciasis. MMGH coordinated the definition…
Client
Bill and Melinda Gates Foundation
Image Credit: IOC/Fiocruz/Gutemberg Brito
2018 — 2018

Development of the business case for a Schistosomiasis vaccine...

MMGH supported the Bill & Melinda Gates Foundation in assessing the public health and financial viability of a vaccine against Schistosomiasis. MMGH coordinated a group of experts in developing vaccine…
Client
Bill and Melinda Gates Foundation
2018 — 2018

Preparation for the Cholera Roadmap implementation...

MMGH assisted the Global Task Force on Cholera Control (GTFCC), supported by a Bill & Melinda Gates Foundation grant, in establishing an oral cholera vaccine (OCV) demand forecast platform, a…
Client
Global Task Force on Cholera Control
Image Credit: Lorenzo Pezzoli
2018 — 2018

Development of the Oral Cholera Vaccine preferred product characteristics...

MMGH supported the WHO Initiative for Vaccine Research (IVR) in updating the Preferred Product Characteristics for the Oral Cholera Vaccine. MMGH facilitated the expert meeting and coordinated the drafting of…
Client
World Health Organisation (WHO)